Arbutus Biopharma stock surged significantly after the company announced a $230 million buyback plan. This move indicates confidence from the company and has been positively received by investors.

Several companies, including Caledonia Mining Corporation Plc, Avino Silver & Gold Mines Ltd., StealthGas Inc., CorMedix Inc., and Arbutus Biopharma Corporation, have reported their financial results for the first quarter of 2026.

Arbutus Biopharma (ABUS) has been granted FDA Fast Track designation for its drug Imdusiran, accelerating its development and review process.

Arbutus Biopharma reported GAAP EPS of -$0.17, missing estimates by $0.13, but revenue of $14.08 million significantly beat estimates by $13.47 million.

Several companies, including SeaStar Medical, Leslie's, and Liftoff Mobile, have released their Q2 2026 earnings, with mixed results regarding EPS and revenue targets. Additionally, previews for Q2 2026 earnings were provided for Global Water Resources, MediWound, and Tecogen.

Arbutus Biopharma announced its GAAP EPS of $0.87 and reported revenue of $179.1 million for the quarter.

Jefferies has lowered its upside potential assessment for Arbutus Biopharma Corporation, citing a higher probability of appeal.

For Genevant Sciences and Arbutus Biopharma, the method used by the American giant is covered by their patent and a license would have been necessary

The article explores whether Arbutus Biopharma Corporation can leverage its settlement with Moderna, Inc. into a long-term competitive advantage within the biotechnology sector.

Arbutus Biopharma has been identified as one of the top 10 biotech penny stocks to consider buying in 2026. This listing is part of a market recommendation.

Arbutus Biopharma announced that its lead drug candidate has received Fast Track designation from the U.S. Food and Drug Administration (FDA).